Advanced Biomed Inc. trades on the Nasdaq Capital Market under the symbol ADVB. In April 2026, the company acquired Acellent Technologies (Hong Kong) Co. Limited, an AI-powered financial verification and audit solutions provider. FinTruth, Acellent's flagship product, is already in production at a top-tier Chinese commercial bank serving roughly 1,000 credit managers daily. Advanced Biomed Inc. 在纳斯达克资本市场以 ADVB 代码交易。2026 年 4 月,公司完成对 AI 金融验证与审计解决方案提供商 Acellent Technologies (Hong Kong) Co. Limited 的收购。Acellent 旗下旗舰产品 FinTruth 已在中国某头部商业银行投入生产,日均服务约 1,000 名信贷经理。
Recent material filings from Advanced Biomed Inc. (NASDAQ: ADVB), the parent company. All filings are publicly available on SEC EDGAR. 母公司 Advanced Biomed Inc. (NASDAQ: ADVB) 近期重大备案文件。所有备案文件可于 SEC EDGAR 系统公开查阅。
Subscribe to receive press releases, SEC filings, and financial reports directly to your inbox as soon as they are published. 订阅后,新闻发布、SEC 备案文件及财务报告将在第一时间发送至您的邮箱。
We will use your information only to send IR communications. You may unsubscribe at any time. See our Privacy Policy. 我们仅将您的信息用于发送 IR 相关通讯。您可随时取消订阅。详见隐私政策。